耳鼻咽喉科・頭頸部外科96巻8号

2024年07月発行

特集 必携！ 唾液腺診療 虎の巻

《唾液腺悪性腫瘍の薬物療法・粒子線治療》

悪性リンパ腫に対する薬物療法

著者： 平川結梨¹ 藥師神公和¹

所属機関： ¹神戸大学大学院医学研究科腫瘍・血液内科学分野

ページ範囲：P.676 - P.679

文献概要

POINT

●唾液腺悪性リンパ腫は比較的稀であるが，唾液腺腫瘤の鑑別疾患の1つである。

●シェーグレン症候群を背景としたMALTリンパ腫の頻度が高い。

●治療は組織型と病期によって決められ，主に化学療法と放射線療法で構成される。

●低悪性度リンパ腫では無治療経過観察が選択肢となることもある。

参考文献

1）Wyss E, et al：Diagnosis and treatment outcomes for patients with lymphoma of the parotid gland. Laryngoscope 123：662-669, 2013

2）Barnes L, et al：Primary malignant lymphoma of the parotid gland. Arch Otolaryngol Head Neck Surg 124：573-577, 1998

3）Zhang XY, et al：Relevance on the diagnosis of malignant lymphoma of the salivary gland. World J Clin Cases 8：2717-2726, 2020

4）間多祐輔・他：唾液腺MALT（mucosa-associated lymphoid tissue）リンパ腫の臨床的検討．日耳鼻118：25-33，2015

5）Kojima M, et al：Primary salivary gland lymphoma among Japanese：a clinicopathological study of 30 cases. Leuk Lymphoma 48：1793-1798, 2007

6）Dunn P, et al：Primary salivary gland lymphoma：a clinicopathologic study of 23 cases in Taiwan. Acta Haematol 112：203-208, 2004

7）Travaglino A, et al：Sjögren syndrome in primary salivary gland lymphoma. Am J Clin Pathol 153：719-724, 2020

8）Carbone PP, et al：Report of the committee on Hodgkin's disease staging classification. Cancer Res 31：1860-1861, 1971

9）日本血液学会（編）：造血器腫瘍診療ガイドライン　2023年版．金原出版，東京，2023

10）Olszewski AJ, et al：Survival of patients with marginal zone lymphoma：analysis of the Surveillance, Epidemiology, and End Results database. Cancer 119：629-638, 2013

11）Flinn IW, et al：First-line treatment of patients with indolent non-hodgkin lymphoma or mantle-cell lymphoma with bendamustine plus rituximab versus R-CHOP or R-CVP：results of the BRIGHT 5-year follow-up study. J Clin Oncol 37：984-991, 2019

12）Zucca E, et al：Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. Blood 101：2489-2495, 2003

13）Thieblemont C, et al：Mucosa-associated lymphoid tissue gastrointestinal and nongastrointestinal lymphoma behavior：analysis of 108 patients. J Clin Oncol 15：1624-1630, 1997

14）Zhang YY, et al：Investigation of the treatment modality in primary lymphoma of the salivary glands. J Stomatol Oral Maxillofac Surg 122：248-255, 2021

15）Gupta A, et al：Primary diffuse large B-cell lymphoma of the major salivary glands：increasing incidence and survival. Am J Otolaryngol 42：102938, 2021

16）Persky DO, et al：Phase Ⅱ study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma：Southwest Oncology Group study 0014. J Clin Oncol 26：2258-2263, 2008

17）Pfreundschuh M, et al：CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma：a randomised controlled trial by the MabThera International Trial（MInT）Group. Lancet Oncol 7：379-391, 2006

18）Tilly H, et al：Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N Engl J Med 386：351-363, 2022

F-FDG PET-CT：a collaborative study by ILROG. Blood 133：237-245, 2019

20）Ardeshna KM, et al：Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma：an open-label randomised phase 3 trial. Lancet Oncol 15：424-435, 2014

21）Rummel MJ, et al：Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas：an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 381：1203-1210, 2013

22）Marcus R, et al：Obinutuzumab for the first-line treatment of follicular lymphoma. N Engl J Med 377：1331-1344, 2017